(Reuters) - Mylan NV (O:MYL) on Tuesday reported slightly higher second quarter profit on increased demand for its generic medicines and specialty drugs, such as its EpiPen injector for severe allergic reactions.
However, for the second successive quarter the company kept in place its full-year forecast for adjusted earnings of $4.85 to $5.15 per share, and its shares fell 1 percent.
Mylan said it could not provide a forecast for net earnings due to an inability "to predict with reasonable certainty" some items, such as expenses related to its recently completed acquisition of Swedish drugmaker Meda for about $7 billion (5 billion pounds).
Mylan posted a net profit of $168.4 million, or 33 cents per share, compared with a profit of $167.8 million, or 32 cents a share, a year ago.
Excluding items, Mylan said it had adjusted earnings of $1.16 per share. Analysts on average had expected $1.13 per share, according to Thomson Reuters I/B/E/S.
Revenue for the quarter rose 8 percent to $2.56, just shy of Wall Street estimates of $2.57 billion.
Mylan shares slipped to $49.40 in extended trading from a Nasdaq close at $49.92.